MX2013005716A - Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma. - Google Patents

Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma.

Info

Publication number
MX2013005716A
MX2013005716A MX2013005716A MX2013005716A MX2013005716A MX 2013005716 A MX2013005716 A MX 2013005716A MX 2013005716 A MX2013005716 A MX 2013005716A MX 2013005716 A MX2013005716 A MX 2013005716A MX 2013005716 A MX2013005716 A MX 2013005716A
Authority
MX
Mexico
Prior art keywords
valsartan
lercanidipine
hydrochloride
lercanidipine hydrochloride
granules
Prior art date
Application number
MX2013005716A
Other languages
English (en)
Spanish (es)
Inventor
Hee Dong Park
Sung Hack Lee
Young Sik Chung
Soo Ah Park
Ree Sun Kim
Sung Ii Kim
Jae Hyeon Juhn
Dong Kyu Kim
Yoo Rin Kim
Seong Jae Park
Ju Hyun Kim
Min Young Jung
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013005716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of MX2013005716A publication Critical patent/MX2013005716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2013005716A 2010-12-09 2011-12-07 Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma. MX2013005716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Publications (1)

Publication Number Publication Date
MX2013005716A true MX2013005716A (es) 2013-06-12

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005716A MX2013005716A (es) 2010-12-09 2011-12-07 Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma.

Country Status (17)

Country Link
EP (1) EP2648730A4 (pt)
KR (1) KR101414814B1 (pt)
CN (1) CN103249415B (pt)
AR (1) AR084195A1 (pt)
AU (1) AU2011339150B2 (pt)
BR (1) BR112013013415A2 (pt)
CL (1) CL2013001626A1 (pt)
CO (1) CO6721030A2 (pt)
DO (1) DOP2013000115A (pt)
EA (1) EA201390844A1 (pt)
IL (1) IL226449A0 (pt)
MX (1) MX2013005716A (pt)
PE (1) PE20140699A1 (pt)
SG (1) SG190326A1 (pt)
UA (1) UA108277C2 (pt)
UY (1) UY33772A (pt)
WO (1) WO2012077968A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
BR112015022103A2 (pt) * 2013-03-12 2017-07-18 Lg Life Sciences Ltd composição farmacêutica, método para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar uma doença
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
WO2005053689A2 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
JP5110697B2 (ja) * 2005-06-27 2012-12-26 第一三共株式会社 固形製剤
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Also Published As

Publication number Publication date
UY33772A (es) 2012-07-31
CN103249415A (zh) 2013-08-14
KR20120089787A (ko) 2012-08-13
SG190326A1 (en) 2013-06-28
EP2648730A2 (en) 2013-10-16
AU2011339150B2 (en) 2015-09-10
DOP2013000115A (es) 2014-07-31
AR084195A1 (es) 2013-04-24
PE20140699A1 (es) 2014-06-13
EA201390844A1 (ru) 2013-11-29
CO6721030A2 (es) 2013-07-31
AU2011339150A1 (en) 2013-06-06
WO2012077968A3 (en) 2012-07-26
EP2648730A4 (en) 2014-08-06
CN103249415B (zh) 2017-12-12
KR101414814B1 (ko) 2014-07-21
BR112013013415A2 (pt) 2019-09-24
IL226449A0 (en) 2013-07-31
CL2013001626A1 (es) 2013-10-04
WO2012077968A2 (en) 2012-06-14
UA108277C2 (ru) 2015-04-10

Similar Documents

Publication Publication Date Title
EP0726766B1 (en) Novel pharmaceutical composition containing the ace inhibitor ramipril and a dihydropyridine compound
JP5344620B2 (ja) オルメサルタンメドキソミル及びアムロジピンの固形製剤
US7741374B1 (en) Methods of use of fenofibric acid
MX2010005680A (es) Composiciones de tapentadol.
AU2011365756B2 (en) Antihypertensive pharmaceutical composition
KR20070085754A (ko) 안정화된 라미프릴 조성물 및 제조 방법
MX2011006009A (es) Composicion farmaceutica solida que comprende amlodipina y losartan y procesos para producir la misma.
US8758815B2 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
EA021317B1 (ru) Монослойные таблетки, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение
KR20150002550A (ko) 타다라필 및 탐수로신을 함유하는 약학적 캡슐 복합 제제
US20090175938A1 (en) Controlled Release Flurbiprofen and Muscle Relaxant Combinations
MX2013005716A (es) Formulacion de un complejo que comprende clorhidrato de lercanidipina y valsartan y metodo para la preparacion de la misma.
EP1673107B1 (en) Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
TW200838503A (en) Pharmaceutical composition
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
EP3886817A1 (en) Pharmaceutical composition comprising ramipril and indapamide
JP2016514125A (ja) バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
KR102486815B1 (ko) Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법
KR102066832B1 (ko) 텔미사르탄 또는 그의 약제학적으로 허용가능한 염을 포함하는 인습성 및 용출률이 향상된 제제
WO2011126327A2 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
TR202019859A1 (tr) Emoksi̇pi̇n ve donepezi̇l i̇çeren farmasöti̇k formülasyonlar
JP2018507176A (ja) Ａｕｃによるオルメサルタン投与のための方法
KR20210152943A (ko) 암로디핀, 로사르탄 및 클로르탈리돈을 단층정에 포함하는 심혈관계 질환의 예방 또는 치료용 약제학적 복합제제
WO2023047203A1 (en) Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent
JP2010174047A (ja) 催眠用圧縮成型製剤